Compare Abeona Therapeutics, Inc. with Similar Stocks
Dashboard
1
Poor long term growth as Operating profit has grown by an annual rate -18.92% of over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
3
With ROE of 41.05%, it has a does not qualify valuation with a 1.57 Price to Book Value
4
High Institutional Holdings at 89.7%
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
USD 268 Million (Micro Cap)
4.00
NA
0.00%
-1.10
41.05%
1.57
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Dec 2025)
Net Profit:
-20 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-16.6%
0%
-16.6%
6 Months
-19.78%
0%
-19.78%
1 Year
-14.17%
0%
-14.17%
2 Years
-41.92%
0%
-41.92%
3 Years
81.89%
0%
81.89%
4 Years
-42.3%
0%
-42.3%
5 Years
-90.69%
0%
-90.69%
Abeona Therapeutics, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-43.59%
EBIT Growth (5y)
-18.92%
EBIT to Interest (avg)
-26.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.56
Sales to Capital Employed (avg)
0.17
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
77.37%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
4
Industry P/E
Price to Book Value
1.57
EV to EBIT
-0.97
EV to EBITDA
-1.01
EV to Capital Employed
-4.93
EV to Sales
80.65
PEG Ratio
0.02
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
41.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 21 Schemes (13.55%)
Foreign Institutions
Held by 34 Foreign Institutions (7.42%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
5.40
0.00
Operating Profit (PBDIT) excl Other Income
-21.80
-23.10
5.63%
Interest
0.90
0.90
Exceptional Items
1.50
2.80
-46.43%
Consolidate Net Profit
-20.50
-5.20
-294.23%
Operating Profit Margin (Excl OI)
-4,227.10%
0.00%
-422.71%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 0.00% vs -100.00% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -294.23% vs -104.78% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
5.80
0.00
Operating Profit (PBDIT) excl Other Income
-85.90
-61.30
-40.13%
Interest
3.70
4.20
-11.90%
Exceptional Items
6.10
-0.80
862.50%
Consolidate Net Profit
71.20
-63.70
211.77%
Operating Profit Margin (Excl OI)
-15,369.10%
0.00%
-1,536.91%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 211.77% vs -17.53% in Dec 2024
About Abeona Therapeutics, Inc. 
Abeona Therapeutics, Inc.
Pharmaceuticals & Biotechnology
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Company Coordinates 
Company Details
1330 Avenue of the Americas Fl 33 , NEW YORK NY : 10019-5442
Registrar Details






